This IP is a therapeutic strategy for facioscapulohumeral dystrophy (FSHD), which is associated with an inappropriate expression of DUX4. Using dual AAV split-intein vectors, it expresses full-length SMCHD1, enhances epigenetic silencing and reduces DUX4 toxicity.